Anti-SDR42E1 monoclonal antibody

Pre-made anti-SDR42E1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SDR42E1/SDR42E1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1589-Ab-1/ GM-Tg-hg-IP1589-Ab-2Anti-Human SDR42E1 monoclonal antibodyHuman
GM-Tg-rg-IP1589-Ab-1/ GM-Tg-rg-IP1589-Ab-2Anti-Rat SDR42E1 monoclonal antibodyRat
GM-Tg-mg-IP1589-Ab-1/ GM-Tg-mg-IP1589-Ab-2Anti-Mouse SDR42E1 monoclonal antibodyMouse
GM-Tg-cynog-IP1589-Ab-1/ GM-Tg-cynog-IP1589-Ab-2Anti-Cynomolgus/ Rhesus macaque SDR42E1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1589-Ab-1/ GM-Tg-felg-IP1589-Ab-2Anti-Feline SDR42E1 monoclonal antibodyFeline
GM-Tg-cang-IP1589-Ab-1/ GM-Tg-cang-IP1589-Ab-2Anti-Canine SDR42E1 monoclonal antibodyCanine
GM-Tg-bovg-IP1589-Ab-1/ GM-Tg-bovg-IP1589-Ab-2Anti-Bovine SDR42E1 monoclonal antibodyBovine
GM-Tg-equg-IP1589-Ab-1/ GM-Tg-equg-IP1589-Ab-2Anti-Equine SDR42E1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1589-Ab-1/ GM-Tg-hg-IP1589-Ab-2; GM-Tg-rg-IP1589-Ab-1/ GM-Tg-rg-IP1589-Ab-2;
GM-Tg-mg-IP1589-Ab-1/ GM-Tg-mg-IP1589-Ab-2; GM-Tg-cynog-IP1589-Ab-1/ GM-Tg-cynog-IP1589-Ab-2;
GM-Tg-felg-IP1589-Ab-1/ GM-Tg-felg-IP1589-Ab-2; GM-Tg-cang-IP1589-Ab-1/ GM-Tg-cang-IP1589-Ab-2;
GM-Tg-bovg-IP1589-Ab-1/ GM-Tg-bovg-IP1589-Ab-2; GM-Tg-equg-IP1589-Ab-1/ GM-Tg-equg-IP1589-Ab-2
Products NameAnti-SDR42E1 monoclonal antibody
Formatmab
Target NameSDR42E1
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SDR42E1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1589-Ag-1Recombinant multi-species D42E1/ SDR42E1/ HSPC105 protein
    ORF Viral VectorpGMLP004078human SDR42E1 Lentivirus plasmid
    ORF Viral VectorvGMLP004078human SDR42E1 Lentivirus particle


    Target information

    Target IDGM-IP1589
    Target NameSDR42E1
    Gene ID93517,74032,307897,714229,489691,101081181,532489,100055715
    Gene Symbol and Synonyms4632417N05Rik,HSPC105,RGD1308481,SDR42E1
    Uniprot AccessionQ8WUS8,Q32L94
    Uniprot Entry NameD42E1_HUMAN,D42E1_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000184860
    Target ClassificationN/A

    The target: SDR42E1, gene name: SDR42E1, also named as HSPC105. Predicted to enable oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor. Predicted to be involved in steroid biosynthetic process. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.